PKI 166

Drug Profile

PKI 166

Alternative Names: CGP 75166

Latest Information Update: 22 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 22 Oct 2002 Discontinued - Phase-II for Solid tumours (unspecified route)
  • 13 Jun 2002 Preclinical studies have been added to the Cancer pharmacodynamics section
  • 18 Oct 2001 A preclinical study has been added to the Cancer pharmacodynamics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top